Let me tell you a story about how modern medicine connects the dots—using BRCA2 as our guide. This is a story that spans decades of research, millions of research dollars, thousands of scientists, and ultimately, lives saved. It's also a perfect demonstration of why Crick's Knowledge Graph exists: to make these connections visible and accessible.
Our story begins in 1994, when researchers isolated and sequenced BRCA2 on chromosome 13. They'd known for years that breast cancer ran in families—too consistently to be chance. The hunt was on for the genetic culprits.
BRCA1 was found in 1990. BRCA2 followed in 1994. Both genes code for proteins involved in DNA repair—specifically, homologous recombination, a high-fidelity repair pathway for double-strand breaks.
Here's what scientists learned about BRCA2:
The clinical significance: Women with pathogenic BRCA2 mutations face:
Men with BRCA2 mutations face:
Families carrying BRCA2 mutations often have multiple members affected across generations—mothers, daughters, sisters, aunts. The pattern is unmistakable and devastating.
In Crick's Knowledge Graph: Start at the BRCA2 gene node. You see connections radiating out to breast cancer, ovarian cancer, prostate cancer, pancreatic cancer. Each edge is labeled with association strength (risk ratios, statistical significance).
Click on BRCA2 and see:
For decades after BRCA2 was discovered, clinical management was crude: enhanced screening (mammograms, MRIs), prophylactic surgery (mastectomy, oophorectomy), and standard chemotherapy if cancer developed.
We knew BRCA2 mutations caused cancer, but we didn't have drugs specifically targeting BRCA2-mutant cells.
Then came an insight from basic science: synthetic lethality.
The concept: Two genetic defects that are individually non-lethal but lethal in combination. If cancer cells have lost BRCA2 function (defect #1), and you pharmacologically block a second DNA repair pathway (defect #2), the cells can't repair DNA at all and die.
The question: What's the second pathway we can block?
Enter PARP.
PARP (Poly ADP-Ribose Polymerase) proteins repair single-strand DNA breaks. They're not the same pathway as BRCA2, but there's crosstalk. Here's the beautiful logic:
Normal cells:
BRCA2-mutant cancer cells:
This is precision medicine in its purest form: a drug that kills cancer cells while sparing normal cells, based on a specific genetic vulnerability.
In Crick's Knowledge Graph: From BRCA2, click through to "DNA Repair" pathway. You see BRCA2 participating in homologous recombination. Nearby in the graph, you see PARP1 participating in base excision repair—a different branch of the DNA damage response.
The connection becomes obvious: these pathways are complementary. Block one in a cell that's already missing the other, and the cell is doomed.
The race was on to develop PARP inhibitors. Multiple pharmaceutical companies pursued the target.
The first to succeed: Olaparib (trade name: Lynparza), developed by AstraZeneca.
Olaparib is a small molecule (molecular weight 435 Daltons) that competitively inhibits PARP1 and PARP2. It looks like NAD+, the natural substrate that PARP binds. When olaparib enters the cell, it occupies PARP's active site, preventing PARP from doing its DNA repair job.
In Crick's Molecule Explorer: View olaparib's structure. You see:
Rotate the 3D structure. The molecule is mostly planar—matching the shape of PARP's binding site.
Compare to other PARP inhibitors (rucaparib, niraparib, talazoparib). They're variations on the same theme: small molecules designed to fit PARP's pocket. Subtle differences in structure lead to differences in potency, side effects, and dosing.
Early studies of olaparib were dramatic. In Phase 1 trials (2005-2008), patients with BRCA-mutant ovarian cancer who'd failed multiple prior treatments saw tumors shrink. Response rates were remarkable for such heavily pre-treated patients.
Phase 2 trials confirmed it: olaparib worked specifically in BRCA-mutant cancers. The synthetic lethality hypothesis, born in yeast genetics labs, was real in humans.
The pivotal Phase 3 trial: SOLO-1 (2013-2018)
Results: Jaw-dropping.
This wasn't incremental improvement. This was transformative.
The FDA approved olaparib for BRCA-mutant ovarian cancer in 2014 (accelerated approval after Phase 2), with full approval following Phase 3 results.
Subsequent trials expanded indications:
In Crick's Clinical Trials: Search for olaparib. You see:
Each trial is a node in the Knowledge Graph, connected to the drug, the diseases, the genes. You can see the evolution: early trials in heavily pre-treated patients, later trials moving to frontline use, ongoing trials exploring broader applications.
The olaparib story didn't end with BRCA2. Researchers realized that synthetic lethality with PARP inhibitors might work for any cancer with defective homologous recombination—not just BRCA mutations.
This concept is called "BRCAness" or "homologous recombination deficiency" (HRD).
Mutations in other genes can also break homologous recombination:
Tumors with these mutations also respond to PARP inhibitors. The FDA now approves olaparib for "HRD-positive" tumors, not just BRCA-mutant ones.
In Crick's Knowledge Graph: Click on "DNA Repair" pathway. You see the full network:
All interconnected. Mutations in multiple nodes can lead to PARP inhibitor sensitivity. The graph shows you the biology as a network, not isolated facts.
Let's make this concrete with a hypothetical but realistic patient:
Sarah, age 42, diagnosed with ovarian cancer.
Her oncologist orders tumor genetic testing (now standard of care). Results: BRCA2 pathogenic mutation.
Sarah goes to Crick and searches "BRCA2." The Knowledge Graph shows:
She clicks on olaparib. Sees:
Her oncologist starts her on standard chemotherapy and surgery. She responds well. Post-treatment, the oncologist recommends olaparib as maintenance therapy—exactly what the SOLO-1 trial tested.
Two years later: Sarah remains cancer-free. She gets MRIs and mammograms more frequently (due to BRCA2 mutation). She's considering prophylactic mastectomy to reduce breast cancer risk.
She also encourages her sister and daughter to get genetic testing. They learn they don't carry the mutation—relief all around.
Five years later: Sarah's cancer has progressed despite olaparib. She returns to Crick and searches for trials. She finds:
She enrolls in a Phase 2 trial testing olaparib + pembrolizumab (immunotherapy). The hypothesis: DNA damage from PARP inhibition creates neoantigens (new proteins) that help the immune system recognize cancer cells.
In the trial: Sarah's cancer stabilizes. She's not cured, but she's living with manageable disease. She's gained years—years to see her daughter graduate college, get married, have kids. Years that wouldn't have existed without understanding the connection between her BRCA2 mutation and PARP inhibitor therapy.
The BRCA2/PARP inhibitor story is far from over. Current frontiers:
Overcoming resistance: Some tumors develop resistance to PARP inhibitors by restoring homologous recombination (reactivating BRCA2 through secondary mutations). Trials are testing combinations to overcome this.
Expanding indications: PARP inhibitors are being tested in any cancer with DNA repair defects—bladder cancer, gastric cancer, bile duct cancer. If the molecular vulnerability is there, the drug might work regardless of tumor type.
Earlier intervention: Can PARP inhibitors prevent cancer in BRCA2 carriers? Prevention trials are underway.
Combination strategies: PARP inhibitors + chemotherapy (causing more DNA damage for PARP to fail at repairing) PARP inhibitors + immunotherapy (increasing tumor antigens) PARP inhibitors + anti-angiogenics (cutting off blood supply while blocking repair)
Next-generation PARP inhibitors: More potent, better tolerated, able to overcome resistance mechanisms.
In Crick: All of these trials are visible and searchable. You can filter:
The Knowledge Graph evolves as science progresses. New trials appear daily. New gene-disease associations are added. New drugs enter testing.
The BRCA2 story demonstrates the full pipeline of precision medicine:
This took 25+ years from gene discovery to FDA approval. And it's still evolving.
For patients like Sarah, understanding these connections isn't academic—it's survival. Knowing she has a BRCA2 mutation explained her cancer, guided her treatment, and opened doors to clinical trials.
For researchers, the Knowledge Graph reveals opportunities:
For drug developers, it shows the competitive and collaborative landscape:
Crick exists because stories like BRCA2→PARP→Olaparib→Clinical Trials are hidden in plain sight. The information is public (NCBI Gene database, PubChem, ClinicalTrials.gov, journal articles), but it's scattered across databases that don't talk to each other.
A patient Googling "BRCA2" gets Wikipedia and medical journals. They don't automatically see:
Crick connects those dots. Not through text explanations, but through visual network exploration. Click BRCA2, see olaparib. Click olaparib, see trials. Click a trial, see eligibility criteria and locations.
The knowledge graph is a map, and you're the explorer.
Explore the BRCA2 network at crick.ai/genes/BRCA2
Discover more articles about precision medicine and biomedical research.
View All Posts